沙库巴曲缬沙坦联合匹伐他汀治疗冠心病合并心力衰竭的临床疗效  

Clinical Efficacy of Sacubitril Valsartan Combined with Pitavastatin in the Treatment of Coronary Heart Disease Complicated with Heart Failure

作　　者：费优生 高洁 张超 徐俊蛟 赵成刚 FEI Yousheng;GAO Jie;ZHANG Chao(Nanxiang Hospital,Jiading District,Shanghai 201802)

机构地区：[1]上海市嘉定区南翔医院,上海201802

出　　处：《医学临床研究》2024年第8期1219-1222,共4页Journal of Clinical Research

摘　　要：【目的】探讨沙库巴曲缬沙坦联合匹伐他汀治疗冠心病(CHD)合并心力衰竭(HF)的临床疗效。【方法】回顾性分析2020年2月至2022年2月本院收治的82例CHD合并HF患者的临床资料,根据治疗方法不同将其分为对照组(在常规治疗的基础上给予匹伐他汀治疗)和观察组(在对照组的基础上给予沙库巴曲缬沙坦治疗),每组41例。比较两组临床疗效、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、6 min步行实验(6MWT)距离、生活质量[明尼苏达心衰生活质量量表(LHFQ)评分],统计治疗期间不良反应发生情况。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组LVEF高于治疗前,LVEDD、LVESD低于治疗前,且观察组与对照组比较,差异均有统计学意义(P<0.05)。治疗后,两组6MWT距离大于治疗前,LHFQ评分低于治疗前,且观察组与对照组比较,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】沙库巴曲缬沙坦联合匹伐他汀治疗CHD合并HF疗效较好,可显著改善患者心功能,提高患者生活质量,且安全性高。【Objective】To investigate the clinical efficacy of sacubitril valsartan combined with pitavastatin in the treatment of coronary heart disease(CHD)with heart failure(HF).【Methods】A retrospective analysis was conducted on the clinical data of 82 patients with CHD combined with HF admitted to our hospital from February 2020 to February 2022.According to the treatment method,they were divided into the control group(treated with pitavastatin in addition to conventional treatment)and the observation group(treated with sacubitril in addition to the control group),with 41 patients in each group.Two groups were compared in terms of clinical efficacy,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD)],6-minute walk test(6MWT)distance,and quality of life[Minnesota Heart Failure Quality of Life Scale(LHFQ score)],and the incidence of adverse reactions during treatment was statistically analyzed.【Results】The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,LVEF in both groups was higher than before treatment,while LVEDD and LVESD were lower than before treatment.The differences between the observation group and the control group were statistically significant(P<0.05).After treatment,the distance between the two groups of 6MWT distarce was greater than before treatment,and the LHFQ score was lower than before treatment.Moreover,the difference between the observation group and the control group was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】The combination of sacubitril valsartan and pitavastatin has a good therapeutic effect on CHD complicated with HF,significantly improving patients'cardiac function,enhancing their quality of life,and has high safety.

关 键 词：冠心病 心力衰竭 缬沙坦 羟甲基戊二酰基COA还原酶抑制剂 

分 类 号：R541.4[医药卫生—心血管疾病]